Pezeshkpoor Behnaz, Fischer Ronald, Preisler Barbara, Hartlieb Katrin, Rühl Heiko, Müller Jens, Horneff Silvia, Marquardt Natascha, Pavlova Anna, Oldenburg Johannes
Institute of Experimental Hematology and Transfusion Medicine, Medical Faculty, University Hospital Bonn, University of Bonn, Bonn, Germany.
Hemophilia Care Center, SRH Kurpfalzkrankenhaus Heidelberg, Heidelberg, Germany.
Haemophilia. 2025 Jan;31(1):140-147. doi: 10.1111/hae.15147. Epub 2024 Dec 19.
Maintaining the balance between procoagulant and anticoagulant factors is essential for effective haemostasis. Emerging evidence suggests a modulation of bleeding tendency by factors in the anticoagulant and fibrinolytic systems.
This study investigates the clinical and laboratory characteristics of a family with combined von Willebrand disease (VWD) and antithrombin (AT) deficiency.
The study focused on a 38-year-old female index patient (IP) with severe type 3 VWD and a history of bleeding disorders. Coagulation assays included VWF antigen, platelet-dependent VWF activity, factor VIII activity, thrombin generation assay (TGA) and AT activity. Molecular genetic analyses were conducted by a targeted DNA custom next generation sequencing (NGS) panel.
The IP and one of her sisters suffered type 3 VWD. While the IP presents with a classical severe bleeding phenotype, the sister (II-2) exhibited less severe bleeding symptoms. Extended family members showed type 1 VWD with mild presentations. NGS revealed a homozygous deletion of exon 6 in the VWF gene in the IP and her sister (II-2). All other family members carry this genetic variant in a heterozygous state. Additionally, II-2 has a heterozygous variant in the SERPINC1 gene (c.133C>T, p.Arg45Trp). Both IP and II-2 carry a homozygous prothrombin G20210A variant. TGA results indicated reduced thrombin generation in severe VWD patients, with a pronounced thrombin burst in those with the AT and prothrombin G20210A variant.
AT deficiency appears to modulate bleeding symptoms in severe VWD. This study emphasizes the importance of comprehensive genetic and phenotypic evaluation in managing complex coagulation disorders.
维持促凝和抗凝因子之间的平衡对于有效的止血至关重要。新出现的证据表明,抗凝和纤溶系统中的因子可调节出血倾向。
本研究调查了一个合并血管性血友病(VWD)和抗凝血酶(AT)缺乏症家族的临床和实验室特征。
该研究聚焦于一名38岁的女性索引患者(IP),她患有严重的3型VWD且有出血性疾病史。凝血检测包括血管性血友病因子(VWF)抗原、血小板依赖性VWF活性、凝血因子VIII活性、凝血酶生成试验(TGA)和AT活性。通过靶向DNA定制下一代测序(NGS)面板进行分子遗传学分析。
IP及其一个姐妹患有3型VWD。IP表现出典型的严重出血表型,而其姐妹(II-2)的出血症状较轻。家族其他成员表现为1型VWD且症状较轻。NGS显示IP及其姐妹(II-2)的VWF基因外显子6纯合缺失。所有其他家族成员均为该基因变异的杂合携带者。此外,II-2的丝氨酸蛋白酶抑制剂C1(SERPINC1)基因存在杂合变异(c.133C>T,p.Arg45Trp)。IP和II-2均携带凝血酶原G20210A纯合变异。TGA结果表明,严重VWD患者的凝血酶生成减少,而同时携带AT和凝血酶原G20210A变异的患者凝血酶爆发明显。
AT缺乏似乎可调节严重VWD的出血症状。本研究强调了在管理复杂凝血障碍中进行全面基因和表型评估的重要性。